Merck & Co. and Schering-Plough received approval from regulators in the US, Canada and Switzerland for their proposed $41.1-billion merger. The companies have already received clearance for the transaction in Europe, while it is still under review in China and Mexico.
In making its ruling, the US Federal Trade Commission ordered Schering-Plough to divest assets related to its treatment for nausea and vomiting in chemotherapy patients, rolapitant, to Opko Health. The commission noted that Merck already has marketed products, Emend Capsules (aprepitant) and Emend Injection (fosaprepitant), in this class of antiemetic drugs, and that the merger would have “reduced the…incentives to launch rolapitant.”
To read more Top Story articles, click here.